Proximie Raises $38m Series B Funding To Accelerate Its Expansion in U.S. and European Markets

Proximie is a health technology platform company focused on digitizing operating and diagnostic rooms.

Today the company announced the completion of its $38 million Series B equity financing. The round was led by F-Prime Capital, with participation from new investors Questa Capital, Eight Roads, Maverick Ventures, and the support of existing investors Global Ventures, BECO Capital, and Cedar Mundi Ventures.

The company’s mission is to save lives by sharing the world’s best clinical practices. The platform combines human expertise with the power of augmented reality (AR), machine learning (ML), artificial intelligence (AI), and advanced telecommunications.

Proximie will use the proceeds to accelerate its expansion in the U.S. and European markets. Significant investment will be directed toward commercial efforts, including new technology implementations, in addition to research and development.

The company was founded by Dr. Nadine Hachach-Haram FRCS (Plastics) – (B.E.M., British Empire Medal), in 2016. The company is building a network of operating rooms, where every interaction is captured, digitized, cataloged, and analyzed. By digitizing surgery, Proximie can accelerate the adoption of best practices and help to create better patient outcomes.

Proximie has enjoyed rapid growth over the last 12 months, having conducted over 10,000 surgical interactions in 300 hospitals in over 40 countries.

SourceProximie
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."
MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.

By using this website you agree to accept Medical Device News Magazine Privacy Policy